Anti-Coagulants - Thailand

Thailand

The Anti-Coagulants market in Thailand is estimated to generate a revenue of €51.70m in 2024.
It is expected to exhibit a compound annual growth rate (CAGR 2024-2029) of 7.90%, leading to a market volume of €75.62m by 2029.
When compared globally, United States is projected to generate the highest revenue in the Anti-Coagulants market, with €15,520.00m in 2024.
Thailand's growing aging population has led to an increased demand for anti-coagulants in the country's healthcare market.

Key regions: Australia, Japan, United States, Germany, Europe

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Anti-Coagulants market in Thailand has been experiencing steady growth in recent years.

Customer preferences: Thai customers are increasingly becoming health-conscious and are taking proactive measures to prevent health issues. This has led to a rise in demand for preventive healthcare products such as Anti-Coagulants. Additionally, with an aging population, there has been an increase in the incidence of cardiovascular diseases, which has further fueled demand for Anti-Coagulants.

Trends in the market: The Anti-Coagulants market in Thailand has seen a shift towards the use of newer oral anticoagulants (NOACs) instead of traditional anticoagulants such as Warfarin. This shift has been driven by the ease of administration and lower risk of complications associated with NOACs. Additionally, there has been an increase in the use of combination therapy, where Anti-Coagulants are used in conjunction with other drugs to prevent blood clots.

Local special circumstances: One of the unique aspects of the Anti-Coagulants market in Thailand is the prevalence of traditional medicine. Many Thai customers prefer to use traditional herbal remedies for their health issues, which can impact the uptake of Anti-Coagulants. However, with increasing awareness about the benefits of modern medicine, this trend is slowly changing.

Underlying macroeconomic factors: Thailand has a rapidly aging population, with a significant proportion of the population over the age of 60. This has resulted in an increase in the incidence of age-related health issues such as cardiovascular diseases, which has in turn driven demand for Anti-Coagulants. Additionally, the Thai government has been investing heavily in healthcare infrastructure, which has led to better access to healthcare services and increased demand for preventive healthcare products such as Anti-Coagulants.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.